Privia Health Group reported significant growth in Q3 and the first nine months of 2026, with net income up 85.9% year-over-year and adjusted EBITDA rising 21.9%. The company raised its full-year 2026 financial guidance above previous estimates, reflecting strong revenue and operational performance. Additionally, Privia expanded its value-based care footprint by acquiring American Choice Healthcare MSSP, adding over 36,000 attributed lives starting in 2027. The company also plans to exit its Montana partnership in early 2027, with minimal impact expected on earnings.
Privia Health's recent report of an 85.9% year-over-year net income increase provides context for readers. For those following the health sector, here is Pluang's market snapshot as of Nov 05, 2026 18:11 WIB: out of 150 priced health-sector US stocks, 85 rose and 56 fell today. Notable movers include Edwards Lifesciences Corporation (EW) at USD 102.62 with a 3.27% gain and a typical hold time of 0 days, Medpace Holdings Inc (MEDP) at USD 677.36 up 3.14% with a 15-day hold, and Natera Inc. (NTRA) at USD 379.00 down 3.08% with a 21-day hold.
On November 4, 2026, Shell plc repurchased a total of 1,876,276 shares across multiple trading venues including LSE, Chi-X, BATS, XAMS, CBOE, and TQEX. The shares were bought at prices ranging from £37.98 to £38.82 and €45.70 to €46.72, with an avera...
Dune has completed a SOC 2 Type II examination with no exceptions, providing institutional clients with verified assurance of its data security standards. This milestone comes as tokenized real-world assets doubled to $32.6 billion and stablecoin mar...
Northern Discovery Metals has finalized the acquisition of a 100% interest in the Cibola copper-gold project in British Columbia from Orogen Royalties. The project covers about 3,567 hectares near Houston, BC, in a region known for porphyry copper de...
Opus Genetics has finished dosing the higher-dose Cohort 2 in its Phase 1/2 trial of OPGx-BEST1, a gene therapy for BEST1-related inherited retinal diseases like Best vitelliform macular dystrophy and autosomal recessive bestrophinopathy. Cohort 2 en...
Perimeter Group Inc. announced a net income of $304.5 million for Q3 2026, reversing a prior year loss of $90.7 million, with net sales up 24% to $389.9 million. Growth was driven by a 14% increase in Fire Safety sales and an 84% surge in Specialty P...
